Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study
Year: 2019
Type: conference-abstract
Source: Cancer Research
Authors: Toni K. Choueiri, David I. Quinn, Tian Zhang, Howard Gurney, Gurjyot K. Doshi, Patrick Wayne Cobb, Francis Parnis, Jae-Lyun Lee, Se Hoon Park, Andrey Semenov, Antoine Thiery-Vuillemin, Piotr Sawrycki, Piotr Tomczak, Boris Alekseev, Adel Izmailov, Wayne Yen-Hwa Chang, Shuyan M. Wan, Christian Heinrich Poehlein, Jaqueline Willemann-Rogerio, Thomas Powles
Institutions: Dana-Farber Cancer Institute, University of Southern California, USC Norris Comprehensive Cancer Center, Duke Cancer Institute, Macquarie University, St. Vincent's HealthCare, Asan Medical Center, University of Ulsan, Samsung Medical Center, Centre Hospitalier Universitaire de Besançon, Provincial Polyclinical Hospital in Toruń, Poznan University of Medical Sciences, Ministry of Health of the Russian Federation, P.A. Hertzen Moscow Oncology Research Institute, Bashkir State Medical University, Taipei Veterans General Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States), Queen Mary University of London, Barts Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2955869300